Streamlining Oncology Prior Authorization with Magellan Healthcare

Navigating prior authorization for complex oncology treatments with Magellan Healthcare requires a precise, automated approach to ensure timely patient access to care.

Oncology workflows present unique prior authorization challenges, from high-cost biologics and radiation therapies to frequent regimen changes. For health systems and clinics managing cancer care, efficient engagement with utilization management entities like Magellan Healthcare is critical for revenue cycle stability and patient outcomes.

Navigating Oncology Prior Authorization with Magellan Healthcare

Oncology prior authorization is characterized by high-cost regimens, frequent treatment adjustments, and stringent documentation requirements. As a Centene-owned utilization management entity, Magellan Healthcare applies specific medical and pharmacy benefit policies that necessitate a streamlined approach to avoid delays in cancer care delivery.

Key Oncology PA Triggers for Magellan Healthcare Review

HCPCS J-codes for chemotherapy, biologics, and immunotherapies, often for each cycle or regimen change.
Advanced imaging, including PET/CT and molecular imaging, for staging and surveillance.
Radiation oncology procedures such as IMRT, IGRT, SBRT, and proton-beam therapy.
Genetic and molecular testing panels for treatment selection and risk stratification.
High-cost supportive care medications, including growth factors and bone-targeting agents.

Documentation Precision for Magellan Healthcare Oncology Reviews

Magellan Healthcare's medical necessity determinations for oncology treatments heavily rely on comprehensive clinical documentation, often aligned with NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium. Submissions must include pathology reports, tumor staging, relevant molecular markers (e.g., ER/PR/HER2, EGFR/ALK, PD-L1), prior-line treatment details, and performance status (ECOG/Karnofsky) to support the requested therapy.

Addressing Magellan Healthcare's Benefit Management for Oncology

Oncology drugs split between medical benefit (provider-administered infusions) and pharmacy benefit (oral oncolytics), each routing through distinct prior authorization channels. Magellan Healthcare, as a key player in both utilization management and pharmacy benefits, requires careful attention to submitting medical benefit PAs via their medical PA channels (e.g., provider portals, X12 278) and pharmacy benefit PAs through their PBM's electronic prior authorization (ePA) partners.

Common Prior Authorization Challenges in Oncology with Magellan Healthcare

Denials for off-label use lacking NCCN Compendium support or specific payer policy alignment.
Step therapy requirements for biologics or oral targeted therapies with less-costly alternatives.
Documentation gaps, such as missing molecular marker results or prior-line treatment responses.
Site-of-service mismatches, directing infusions to specific care settings.
The high volume of peer-to-peer reviews for clinical-necessity denials, impacting oncologist time.

Klivira's Platform for Streamlined Oncology Prior Authorization with Magellan Healthcare

Klivira's prior authorization automation platform is engineered to address the complexities of oncology workflows when interacting with payers like Magellan Healthcare. Our system integrates NCCN-compendium-aware policy logic, manages regimen-level PA submissions, intelligently routes medical vs. pharmacy benefit requests, and tracks the numerous concurrent PA events typical for cancer patients, reducing administrative burden and accelerating treatment initiation.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for oncology drugs under Magellan Healthcare?

Klivira's platform intelligently identifies the benefit type for each oncology medication. For medical benefit drugs (e.g., IV infusions), we route submissions through Magellan Healthcare's medical PA channels. For pharmacy benefit oral oncolytics, we integrate with ePA partners to ensure proper submission to Magellan's PBM.

Can Klivira help with documentation requirements for Magellan Healthcare oncology PAs?

Yes, Klivira incorporates NCCN-compendium-aware policy logic to highlight required documentation based on the specific regimen and tumor type at the point of order entry. This proactive guidance helps ensure all necessary pathology, staging, and molecular marker details are included for Magellan Healthcare's review.

How does Klivira address the high volume of PA events per oncology patient when dealing with Magellan Healthcare?

Klivira provides concurrent PA tracking capabilities, allowing clinics to manage and monitor dozens of PA events per patient across diagnosis, treatment changes, supportive care, and surveillance imaging. This ensures no PA is missed and provides a comprehensive overview of authorization statuses with Magellan Healthcare.

Does Klivira assist with peer-to-peer reviews for Magellan Healthcare oncology denials?

Klivira's platform includes features designed to streamline the peer-to-peer review process, such as scheduling integration for oncologist-payer reviews. While Klivira does not conduct the review, it facilitates the operational aspects to minimize delays caused by clinical-necessity denials from Magellan Healthcare.

How does Klivira support urgent oncology treatment starts with Magellan Healthcare?

By automating manual PA tasks and providing real-time status updates, Klivira significantly reduces the administrative cycle time for prior authorizations. This acceleration helps clinics secure approvals from Magellan Healthcare more rapidly, directly supporting the critical diagnosis-to-treatment-start intervals essential in oncology.